Clinical Trials
19 trialsNCT06904625 2026-05-27
CAPT CTC
Institut Claudius Regaud
Phase NA Recruiting
NCT04771871 2026-05-07
TARMAC
University College Hospital, Ibadan
Phase 2 Recruiting
NCT06807502 2026-04-24
PROBE-CTC
ScreenCell
Phase NA Recruiting
NCT06067503 2026-04-13
Biomarkers to Detect Endocrine Therapy Resistance
University of Wisconsin, Madison
Phase 2 Recruiting
NCT07418125 2026-02-18
GALIA
Institute of Oncology Ljubljana
Phase NA Recruiting
NCT05360290 2026-02-03
CTCNeoBC-E
RenJi Hospital
Phase NA Recruiting
NCT02958852 2025-09-10
ABC-SE
Lund University Hospital
Phase 2 Completed
NCT01015625 2024-08-19
POSYTIVE
Austrian Breast & Colorectal Cancer Study Group
Phase NA Completed
NCT01619111 2024-06-04
DETECT III
University of Ulm
Phase 3 Completed
NCT02035813 2024-06-04
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
University of Ulm
Phase 2 Completed
NCT03928210 2023-12-13
Digoxin Induced Dissolution of CTC Clusters
University Hospital, Basel, Switzerland
Phase EARLY_PHASE1 Completed
NCT04993014 2021-08-06
HER2Cell
AC Camargo Cancer Center
Phase 2 Recruiting
NCT01548677 2019-03-13
TREAT-CTC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02941536 2018-12-27
Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer
AC Camargo Cancer Center
Phase NA Completed
NCT03070002 2018-11-20
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Northwestern University
Phase 2 Terminated
NCT01710605 2018-04-09
Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers
Institut Curie
Phase 3 Unknown
NCT02602938 2015-11-13
ACABC
Zhejiang Provincial People's Hospital
Phase 2 Unknown
NCT01129336 2014-05-20
MACS1295
Novartis
Phase 4 Completed
NCT00429182 2013-04-10
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed